首页|期刊导航|南京医科大学学报(自然科学版)|慢性粒单核细胞白血病合并淋巴/浆细胞肿瘤9例临床分析

慢性粒单核细胞白血病合并淋巴/浆细胞肿瘤9例临床分析OA

Chronic myelomonocytic leukemia patients co-occurrent with lymphoid/plasma cell neoplasms:a clinical analysis of 9 cases

中文摘要英文摘要

目的:描述慢性粒单核细胞白血病(chronic myelomonocytic leukemia,CMML)合并淋巴/浆细胞肿瘤患者的临床特征及预后情况.方法:回顾性分析2016年1月-2025年8月于南京医科大学第一附属医院就诊的9例合并淋巴/浆细胞肿瘤的 CMML(lymphoma/plasma cell neoplasms with CMML,LP-CMML)患者资料,并与年龄匹配的 36 例原发 CMML(de novo CMML,DN-CMML)进行比较.结果:LP-CMML患者中位年龄66(58,76)岁,8例(88.9%)为男性,所有患者均为CMML-1,合并的淋巴/浆细胞肿瘤以弥漫大B细胞淋巴瘤最常见(3例).LP-CMML与DN-CMML患者在基本临床特征、细胞遗传学风险分层及疾病危险分层分布上差异均无统计学意义.按照两种恶性肿瘤发生时序将患者分为治疗相关CMML(therapy related CMML,tCMML)4例,非tCMML5例,tCMML患者较非tCMML更年轻(P=0.016),且以发育异常型为主(P=0.048).对1例tCMML患者进行动态基因检测显示,其在淋巴系统肿瘤诊断时即存在CMML前驱状态,并在病程中发生克隆演变.生存分析显示,LP-CMML患者中位总生存期(6个月vs.40个月,P<0.001)与中位无进展生存期(5个月vs.29个月,P<0.001)均显著短于DN-CMML患者,亚组分析示tCMML与非tCMML患者生存无显著差异.结论:LP-CMML患者存在临床异质性且预后不佳.

Objective:To describe the clinical characteristics and prognosis of chronic myelomonocytic leukemia(CMML)patients co-occurrent with lymphoid/plasma cell neoplasms(LP-CMML).Methods:We retrospectively identified nine LP-CMML cases who visited the First Affiliated Hospital of Nanjing Medical University between January 2016 and August 2025,and compared their features with de novo CMML(DN-CMML).Results:The median age of LP-CMML patients was 66(58,76)years,with 8(88.9%)being male.All patients were classified as CMML-1.The most common co-existing lymphoid/plasma cell neoplasm was diffuse large B-cell lymphoma(3 cases).No differences were found between LP-CMML and DN-CMML in basic clinical characteristics,cytogenetic risk stratification and disease risk stratification.Based on the sequence of occurrence,4 patients were classified as therapy-related CMML(tCMML)and 5 as non-tCMML.Compared with the non-tCMML patients,tCMML patients were younger(P=0.016)and the dysplastic phenotype predominance(P=0.048).Dynamic monitoring of one tCMML patient revealed a pre-existing CMML precursor state at the time of lymphoid neoplasm diagnosis,with clonal evolution during the disease course.Survival analysis showed shorter median overall survivals(6 months vs.40 months,P<0.001)and median progression free survivals(5 months vs.29 months,P<0.001)for LP-CMML than those of DN-CMML.No difference was found in survivals between tCMML and non-tCMML subgroups.Conclusion:LP-CMML indicates clinical heterogeneity and poor survival.

史仲珣;范磊;沈文怡;黄菲;朱华渊;洪鸣;屈晓燕;陈妤;王蓉;王琰;严怡宁

南京医科大学第一附属医院血液科,江苏 南京 210029南京医科大学第一附属医院血液科,江苏 南京 210029南京医科大学第一附属医院血液科,江苏 南京 210029南京医科大学第一附属医院血液科,江苏 南京 210029南京医科大学第一附属医院血液科,江苏 南京 210029南京医科大学第一附属医院血液科,江苏 南京 210029南京医科大学第一附属医院血液科,江苏 南京 210029南京医科大学第一附属医院血液科,江苏 南京 210029南京医科大学第一附属医院血液科,江苏 南京 210029南京医科大学第一附属医院血液科,江苏 南京 210029南京医科大学第一附属医院血液科,江苏 南京 210029

医药卫生

慢性粒单核细胞白血病淋巴/浆细胞肿瘤临床特征预后

chronic myelomonocytic leukemialymphoid/plasma cell neoplasmsclinical characteristicsprognosis

《南京医科大学学报(自然科学版)》 2026 (8)

1145-1153,9

国家自然科学基金(82200151)

10.7655/NYDXBNSN251478

评论